Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Pancreatic Neuroendocrine Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01229943
What this trial is testing

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

Who this might be right for
Advanced Pancreatic Neuroendocrine TumorLocally Advanced Pancreatic Neuroendocrine TumorPancreatic Gastrinoma+3 more
National Cancer Institute (NCI) 150
Early research (Phase 1)Study completedNCT03849469
What this trial is testing

XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Who this might be right for
MelanomaCervical CarcinomaPancreatic Carcinoma+20 more
Xencor, Inc. 78
Testing effectiveness (Phase 2)Temporarily pausedNCT06202066
What this trial is testing

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Who this might be right for
Digestive System Neuroendocrine NeoplasmLung Neuroendocrine NeoplasmMalignant Solid Neoplasm+1 more
Roswell Park Cancer Institute 60
Not applicableUnknownNCT03517332
What this trial is testing

Circulating Tumor DNA Exposure in Peripheral Blood

Who this might be right for
Colorectal CancerPancreatic AdenocarcinomaGastric Cancer+8 more
Quantgene Inc. 10,000
Not applicableEnded earlyNCT04106167
What this trial is testing

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Who this might be right for
Advanced Solid TumorLymphomaGastric Cancer+15 more
Fate Therapeutics 20
Early research (Phase 1)Study completedNCT00073944
What this trial is testing

BCX-1777 in Treating Patients With Refractory Cancer

Who this might be right for
Cancer
BioCryst Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT02575300
What this trial is testing

Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Who this might be right for
Carcinoid TumorsPancreatic NET
H. Lee Moffitt Cancer Center and Research Institute 20
Not applicableStudy completedNCT01135849
What this trial is testing

B-Receptor Signaling in Cardiomyopathy

Who this might be right for
CarcinomasAmyloidosisAnal Cancer+35 more
Daniel Bernstein 99
Testing effectiveness (Phase 2)UnknownNCT02038738
What this trial is testing

68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors

Who this might be right for
NeuroendocrineNeuroendocrine TumorNeuroendocrine Cancer+5 more
Ochsner Health System 250
Not applicableActive Not RecruitingNCT00835133
What this trial is testing

Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and Melanoma

Who this might be right for
Familial Pancreatic Cancer
Mayo Clinic 1,122
Early research (Phase 1)Study completedNCT00006368
What this trial is testing

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Who this might be right for
Brain and Central Nervous System TumorsBreast CancerGastrointestinal Carcinoid Tumor+5 more
Novartis Pharmaceuticals 60
Testing effectiveness (Phase 2)Study completedNCT04068896
What this trial is testing

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

Who this might be right for
Pancreatic CancerMetastatic Castration-resistant Prostate CancerBladder Cancer+8 more
NGM Biopharmaceuticals, Inc 89
Testing effectiveness (Phase 2)UnknownNCT02455596
What this trial is testing

Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences 20
Testing effectiveness (Phase 2)Study completedNCT05708950
What this trial is testing

A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Who this might be right for
CancerSolid TumorMelanoma+14 more
Kineta Inc. 40
Not applicableLooking for participantsNCT03452774
What this trial is testing

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Who this might be right for
Cancer, MetastaticCancerCancer of Pancreas+40 more
Massive Bio, Inc. 50,000
Not applicableStudy completedNCT00477919
What this trial is testing

E-MOSAIC Electronic Tool to Monitor Symptoms

Who this might be right for
Cancer
Swiss Cancer Institute 264
Not applicableLooking for participantsNCT06735560
What this trial is testing

Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN

Who this might be right for
Hepatocellular Carcinoma (HCC)Intrahepatic Cholangiocarcinoma (Icc)Neuroendocrine Tumors
Nantes University Hospital 60
Not applicableUnknownNCT03033186
What this trial is testing

Everolimus TDM to Predict Long Term Toxicity

Who this might be right for
Breast CancerRenal Cell CarcinomaPancreatic Neuroendocrine Tumour+2 more
Maastricht University Medical Center 40
Early research (Phase 1)Ended earlyNCT02313012
What this trial is testing

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Who this might be right for
Neoplasm Metastasis
Celgene 19
Testing effectiveness (Phase 2)Study completedNCT02893930
What this trial is testing

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

Who this might be right for
Pancreatic Neuroendocrine Tumor G1Pancreatic Neuroendocrine Tumor G2Refractory Pancreatic Neuroendocrine Carcinoma
National Cancer Institute (NCI) 13
Next Page